Logo
x

Search category

Subscribe Now

Sanofi

Sanofi Reports P-II Study Results of Frexalimab for the Treatment of Relapsing Multiple Sclerosis

Sanofi Reports P-II Study Results of Frexalimab for the Treatment of Relapsing Multiple Sclerosis

  • June 1, 2023
PharmaShots Weekly Snapshots (May 08 - 12, 2023)

PharmaShots Weekly Snapshots (May 08 - 12, 2023)

  • May 13, 2023
Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD

Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD

  • May 12, 2023
Sanofi and Regeneron Report P-III Trial (PRIME) and (PRIME2) Results of Dupixent (dupilumab) for the Treatment of Prurigo Nodularis

Sanofi and Regeneron Report P-III Trial (PRIME) and (PRIME2) Results of Dupixent (dupilumab) for the Treatment of Prurigo Nodulari...

  • May 9, 2023
Sanofi’s Dupixent (dupilumab) Receives Health Canada’s Approval for Adults and Adolescent Patients Aged ≥12 Years with Eosinophilic Esophagitis

Sanofi’s Dupixent (dupilumab) Receives Health Canada’s Approval for Adults and Adolescent Patients Aged ≥12 Years with Eosinophili...

  • May 5, 2023
Top Performing Drug – Dupixent (April Edition)

Top Performing Drug – Dupixent (April Edition)

  • April 26, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.